RARα2 expression confers myeloma stem cell features.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Stem Cells

Background:

• Retinoic acid receptor alpha 2 (RARα2) expression is elevated in relapsed multiple myeloma (MM) and associated with poor prognosis in newly diagnosed patients.
• RARα2's role in multiple myeloma stem cell (MMSC) biology and drug resistance is not fully understood.

Purpose of the Study:

• To investigate the role of RARα2 in conferring multiple myeloma stem cell characteristics.
• To elucidate the mechanisms by which RARα2 induces drug resistance.
• To evaluate therapeutic strategies targeting RARα2 and its associated pathways in preclinical models.

Main Methods:

• Assessed RARα2 expression in MMSC fractions.
• Overexpressed and knocked down RARα2 in MM cell lines to evaluate functional consequences.
• Analyzed activation of Wnt and Hedgehog (Hh) signaling pathways.
• Measured drug resistance, side population, aldehyde dehydrogenase activity, and embryonic stem cell gene expression.
• Utilized the 5TGM1 mouse model to test therapeutic interventions targeting Wnt/Hh pathways.

Main Results:

• Higher RARα2 expression was found in the MMSC fraction.
• RARα2 overexpression increased drug resistance, clonogenic potential, side population, and aldehyde dehydrogenase levels, while activating Wnt/Hh pathways and upregulating embryonic stem cell genes.
• RARα2 induced drug resistance via ABCC3 and Bcl-2 family members; Wnt signaling or ABCC3 inhibition overcame this resistance.
• In vivo, targeting Wnt/Hh pathways reduced tumor burden and improved survival in the 5TGM1 mouse model.

Conclusions:

• Increased RARα2 expression drives multiple myeloma stem cell properties, including drug resistance and pathway activation.
• Targeting RARα2 or its downstream Wnt and Hh signaling pathways presents a promising therapeutic strategy for eliminating MMCs and overcoming treatment resistance.